Agar and broth microdilution MICs of Ro 23-9424 that inhibited 90% of 22 LegioneUla clinical isolates tested were 0.64 and 0.08 ,ug/ml, respectively; respective erythromycin values were 1.0 and 0.12 jglml. Ro (1 jg/ml) was slightly more active than the same erythromycin concentration in a macrophage system, for both Legionela pneumophila strains studied.
control organisms for susceptibility testing. Legionellae were grown on locally made buffered charcoal-yeast extract medium supplemented with 0.1% a-ketoglutarate (BCYEa) (3) . Incubation of all media was done at 35°C in humidified air. Standard powders of Ro 23-9424 and fleroxacin were obtained from Hoffmann-LaRoche, Inc., Nutley, N.J.; erythromycin powder was obtained from Abbott Laboratories, North Chicago, Ill.
Agar dilution susceptibility testing was performed as described previously (5 105 CFU/ml (3). Otherwise, the microdilution method was performed exactly as described previously for a macrodilution method (5 Guinea pig pulmonary alveolar macrophages were harvested and purified as described previously (5) . The final concentration of macrophages was approximately 105 cells per well. Antimicrobial susceptibility testing of intracellular L. pneumophila was performed as described previously (5) . Briefly, 104 CFU of washed BCYEa plate-grown L. pneumophila was added to the purified alveolar macrophages. The bacteria and macrophages were incubated for 1 day after 1 h of incubation with shaking. Antimicrobial agents were added to the respective wells, after the wells had been washed three times to remove nonadherent bacteria. Sonic extracts of two replicate, non-antimicrobial agent-containing wells were quantitatively cultured for use as the day 1 bacterial count. Non-antimicrobial agent-containing wells were used as growth controls. After 2 more days of incubation, the supernatants were sampled and quantitatively cultured; all wells were then washed to remove antimicrobial agents. Bacterial counts in the supematant of each well were determined for another 4 days. To check for antimicrobial agent toxicity, uninfected macrophages were incubated with the highest concentration of antimicrobial agent tested and observed microscopically daily. The relative activities of Ro 23-9424 and fleroxacin were determined for one L. pneumophila strain; the activity of fleroxacin alone (0.5 jig/ml) was contrasted to that of the combination drug (1 ,ug/ml). The fleroxacin extracellular broth microdilution MIC for L. pneumophila strain F2111 is 0.02 ,ug/ml (6) . All experiments were carried out in triplicate, and quantitative plating was carried out in duplicate.
Ro 23-9424 and erythromycin agar and broth microdilution MICs for the 22 Legionella strains tested are shown in Table  1 . A single L. micdadei strain did not grow well enough in BYEa broth for broth microdilution testing to be performed, allowing only 21 Legionella strains to be tested by this method. The erythromycin broth microdilution MIC for another L. micdadei strain (0.5 ,g/ml) was much higher than that for any other strain tested. Erythromycin broth micro- (6) and cefotaxime MICgs of 4 and .0.12 p,g/ml by agar and broth microdilutions, respectively, for different L. pneumophila strains (10, 12) . Since we did not test equimolar concentrations of the two Ro 23-9424 components, it is unknown how similar the activity of the combination drug is to that of the combined free components.
The intracellular activity of Ro 23-9424 and erythromycin for two L. pneumophila serogroup 1 strains grown in guinea pig alveolar macrophages is shown in Fig. 1 and 2 . For L. pneumophila strain F889 (Fig. 1) , both drugs were only inhibitory in their activity, although there was a significantly longer postantibiotic effect observed for Ro 23-9424. Both erythromycin and Ro 23-9424 were similar in their inhibitory activity for L. pneumophila F2111 (Fig. 2) . Fleroxacin alone (0.5 ,g/ml) was more active than Ro 23-9424 (1.0 ,g/ml), although the fleroxacin concentration was the same in both the single and combination drugs. The slight decrease in viable counts of strain F2111 observed on day 5, for eryth- romycin and Ro 23-9424 (both 0.25 ,ug/ml), is artifactual because of macrophage killing by the bacteria by day 3; many of the bacteria in these tissue culture wells were washed out with the damaged macrophages. Macrophage toxicity caused by antimicrobial agents alone was not observed.
These studies show that Ro 23-9424 is about as active as erythromycin for both extracellular and intracellular Legionella spp., with neither drug being bactericidal. The significantly greater activity of fleroxacin than that of the combination drug is probably related to limited extracellular hydrolysis of the combination drug, which releases free fleroxacin. The free fleroxacin is probably more concentrated in macrophages than is the combination drug. Because L. pneumophila is protected from extracellular antimicrobial agents by its intracellular location in the lungs and elsewhere in the body, the in vitro activity of drugs against intracellular L. pneumophila is generally a good predictor of their clinical activity. Ro 23-9424 has potential use for the treatment of Legionnaires' disease, and possibly other intracellular infections, pending animal model treatment studies and clinical trials. Whether the combination drug would be more or less clinically effective than erythromycin can only be determined by comparative clinical studies.
